The accelerated approval pathway in oncology: Balancing the benefits and potential harms.
Author:
Publisher
Elsevier BV
Subject
Health Policy,Oncology
Reference10 articles.
1. Food and Drug Administration, Accelerated Approval, 2018, 〈https://www.fda.gov/ForPatients/Approvals/Fast/ucm405447.htm〉 (accessed 3 April 2019).
2. A 25-year experience of US Food and Drug Administration accelerated approval of malignant hematology and oncology drugs and biologics: a review;Beaver;JAMA Oncol.,2018
3. A systematic review of trial-level meta-analyses measuring the strength of association between surrogate end-points and overall survival in oncology;Haslam;Eur. J. Cancer,2019
4. Patient perspectives of value of delayed disease progression on imaging (imaging PFS). A treatment trade-off experiment;Robinson;J. Cancer Policy,2021
5. The US Food and Drug Administration’s Approval of Adjuvant Sunitinib for Renal Cell Cancer: A Case of Regulatory Capture?;Gyawali;JAMA Oncol.,2018
Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Beschleunigte Zulassungsverfahren: Status quo, Probleme und Reformbedarf;InFo Hämatologie + Onkologie;2022-09
2. Implications of Oncology Trial Design and Uncertainties in Efficacy-Safety Data on Health Technology Assessments;Current Oncology;2022-08-16
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3